Mesoblast Limited (ASX:MSB) Insider Buys A$14,830,544.03 in Stock

Mesoblast Limited (ASX:MSB) insider Gregory George acquired 5,034,129 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were purchased at an average cost of A$2.95 ($1.86) per share, with a total value of A$14,830,544.03 ($9,386,420.27).

Mesoblast Price Performance

The company has a quick ratio of 1.82, a current ratio of 1.18 and a debt-to-equity ratio of 24.76. The firm has a market cap of $2.32 billion, a price-to-earnings ratio of -23.29, a price-to-earnings-growth ratio of 9.56 and a beta of 2.38.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.